Published in J Bone Miner Res on November 01, 2010
Bisphosphonate Users Radiographic Characteristics of the Hip (BURCH) Study | NCT01360099
Exome Sequencing for Atypical Femoral Fractures | NCT02731040
Treatment With Zoledronic Acid Subsequent to Denosumab in Osteoporosis (ZOLARMAB) | NCT03087851
The Effects of Fragility Fracture Integrated Rehabilitation Management | NCT04760756
2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary. CMAJ (2010) 6.37
European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int (2012) 4.88
The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT). J Bone Miner Res (2012) 4.15
Pathophysiology of atypical femoral fractures and osteonecrosis of the jaw. Osteoporos Int (2011) 2.49
American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the diagnosis and treatment of postmenopausal osteoporosis. Endocr Pract (2011) 2.29
Bisphosphonates and nonhealing femoral fractures: analysis of the FDA Adverse Event Reporting System (FAERS) and international safety efforts: a systematic review from the Research on Adverse Drug Events And Reports (RADAR) project. J Bone Joint Surg Am (2013) 2.29
Reduced cortical bone compositional heterogeneity with bisphosphonate treatment in postmenopausal women with intertrochanteric and subtrochanteric fractures. J Bone Miner Res (2012) 2.05
Bisphosphonate use and increased incidence of subtrochanteric fracture in South Korea: results from the National Claim Registry. Osteoporos Int (2012) 1.84
Changes in bone resorption across the menopause transition: effects of reproductive hormones, body size, and ethnicity. J Clin Endocrinol Metab (2013) 1.69
Bisphosphonates and risk of subtrochanteric, femoral shaft, and atypical femur fracture: a systematic review and meta-analysis. J Bone Miner Res (2013) 1.66
Bisphosphonates for treatment of osteoporosis: expected benefits, potential harms, and drug holidays. Can Fam Physician (2014) 1.63
The effect of three or six years of denosumab exposure in women with postmenopausal osteoporosis: results from the FREEDOM extension. J Clin Endocrinol Metab (2013) 1.60
Osteoporosis imaging: state of the art and advanced imaging. Radiology (2012) 1.58
Adverse reactions and drug-drug interactions in the management of women with postmenopausal osteoporosis. Calcif Tissue Int (2011) 1.50
Managing Osteoporosis in Patients on Long-Term Bisphosphonate Treatment: Report of a Task Force of the American Society for Bone and Mineral Research. J Bone Miner Res (2016) 1.50
UK clinical guideline for the prevention and treatment of osteoporosis. Arch Osteoporos (2017) 1.40
A framework for the development of guidelines for the management of glucocorticoid-induced osteoporosis. Osteoporos Int (2012) 1.36
The effect of 8 or 5 years of denosumab treatment in postmenopausal women with osteoporosis: results from the FREEDOM Extension study. Osteoporos Int (2015) 1.29
Osteoporosis - a current view of pharmacological prevention and treatment. Drug Des Devel Ther (2013) 1.29
Odanacatib for the treatment of postmenopausal osteoporosis: development history and design and participant characteristics of LOFT, the Long-Term Odanacatib Fracture Trial. Osteoporos Int (2014) 1.29
Low-energy diaphyseal femoral fractures associated with bisphosphonate use and severe curved femur: a case series. J Bone Miner Metab (2012) 1.18
Atypical fractures do not have a thicker cortex. Osteoporos Int (2012) 1.17
Individualizing osteoporosis therapy. Osteoporos Int (2012) 1.15
Bilateral atypical femoral fractures: how much symmetry is there on imaging? Skeletal Radiol (2015) 1.14
The effect of long-term alendronate treatment on cortical thickness of the proximal femur. Clin Orthop Relat Res (2011) 1.10
Sex and gender considerations in male patients with osteoporosis. Clin Orthop Relat Res (2011) 1.08
Antiresorptive therapies for osteoporosis: a clinical overview. Nat Rev Endocrinol (2011) 1.04
Atypical femoral fracture risk in patients treated with bisphosphonates. Arch Intern Med (2012) 1.03
Feeding blueberry diets in early life prevent senescence of osteoblasts and bone loss in ovariectomized adult female rats. PLoS One (2011) 1.02
Femoral stress fractures associated with long-term bisphosphonate treatment. Clin Orthop Relat Res (2012) 1.01
Pseudoarthrosis in atypical femoral fracture: case report. Osteoporos Int (2013) 1.01
Screening, diagnosis and treatment of osteoporosis: a brief review. Clin Cases Miner Bone Metab (2014) 0.99
Bisphosphonate prescribing, persistence and cumulative exposure in Ontario, Canada. Osteoporos Int (2011) 0.96
Risk of femoral shaft and subtrochanteric fractures among users of bisphosphonates and raloxifene. Osteoporos Int (2010) 0.96
Atypical femoral fractures after anti-osteoporotic medication: a Korean multicenter study. Int Orthop (2014) 0.95
Should bisphosphonates be used for long-term treatment of glucocorticoid-induced osteoporosis? Arthritis Rheum (2011) 0.95
Bone tissue composition varies across anatomic sites in the proximal femur and the iliac crest. J Orthop Res (2011) 0.95
The resistance of cortical bone tissue to failure under cyclic loading is reduced with alendronate. Bone (2014) 0.94
Trends in subtrochanteric, diaphyseal, and distal femur fractures, 1984-2007. Osteoporos Int (2011) 0.94
Atypical subtrochanteric femoral shaft fractures: role for mechanics and bone quality. Arthritis Res Ther (2012) 0.94
Risk factors for subtrochanteric and diaphyseal fractures: the study of osteoporotic fractures. J Clin Endocrinol Metab (2013) 0.94
Endocrine and metabolic manifestations in inflammatory bowel disease. Ann Gastroenterol (2012) 0.93
Targeting the LRP5 pathway improves bone properties in a mouse model of osteogenesis imperfecta. J Bone Miner Res (2014) 0.93
The incidence of and risk factors for developing atypical femoral fractures in Japan. J Bone Miner Metab (2014) 0.93
Bisphosphonate treatment and risk of esophageal cancer: a meta-analysis of observational studies. Osteoporos Int (2012) 0.92
SHP2 regulates osteoclastogenesis by promoting preosteoclast fusion. FASEB J (2015) 0.92
Validation of diagnostic codes for subtrochanteric, diaphyseal, and atypical femoral fractures using administrative claims data. J Clin Densitom (2011) 0.91
Rare non-traumatic periprosthetic femoral fracture with features of an atypical femoral fracture: a case report. J Med Case Rep (2015) 0.90
For whom the bell tolls: distress signals from long-lived osteocytes and the pathogenesis of metabolic bone diseases. Bone (2012) 0.90
Bone microdamage, remodeling and bone fragility: how much damage is too much damage? Bonekey Rep (2015) 0.89
Three years of treatment with minodronate in patients with postmenopausal osteoporosis. J Bone Miner Metab (2011) 0.89
Racial/ethnic differences in hip and diaphyseal femur fractures. Osteoporos Int (2014) 0.89
Long-term fracture rates seen with continued ibandronate treatment: pooled analysis of DIVA and MOBILE long-term extension studies. Osteoporos Int (2013) 0.88
American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the diagnosis and treatment of postmenopausal osteoporosis: executive summary of recommendations. Endocr Pract (2011) 0.88
Atypical femoral fractures: epidemiology, etiology, and patient management. Curr Opin Support Palliat Care (2012) 0.88
Effect of Teriparatide on Healing of Atypical Femoral Fractures: A Systemic Review. J Bone Metab (2015) 0.88
Stress fracture of the pelvis and lower limbs including atypical femoral fractures-a review. Insights Imaging (2014) 0.88
Osteoclast abnormalities in fractured bone during bisphosphonate treatment for osteoporosis: a case report. Skeletal Radiol (2012) 0.87
Management strategy for symptomatic bisphosphonate-associated incomplete atypical femoral fractures. HSS J (2012) 0.87
Skeletal complications of bisphosphonate use: what the radiologist should know. Br J Radiol (2012) 0.87
Do bisphosphonates cause femoral insufficiency fractures? J Orthop Traumatol (2012) 0.87
Influence of treatment with alendronate on the speed of sound, an ultrasound parameter, of the calcaneus in postmenopausal Japanese women with osteoporosis: a clinical practice-based observational study. Ther Clin Risk Manag (2012) 0.87
Management of osteoporosis of the oldest old. Osteoporos Int (2014) 0.87
Dichotomous location of 160 atypical femoral fractures. Acta Orthop (2013) 0.87
Incidence of fractures of the femur, including subtrochanteric, up to 8 years since initiation of oral bisphosphonate therapy: a register-based cohort study using the US MarketScan claims databases. Osteoporos Int (2012) 0.86
Increased vertebral morphometric fracture in patients with postsurgical hypoparathyroidism despite normal bone mineral density. BMC Endocr Disord (2013) 0.86
Atypical femoral fractures. Clin Cases Miner Bone Metab (2013) 0.86
Are women with thicker cortices in the femoral shaft at higher risk of subtrochanteric/diaphyseal fractures? The study of osteoporotic fractures. J Clin Endocrinol Metab (2012) 0.86
Crucial Role of Vitamin D in the Musculoskeletal System. Nutrients (2016) 0.85
Pharmacological management of osteogenesis. Clinics (Sao Paulo) (2014) 0.85
Quantitative relationships between microdamage and cancellous bone strength and stiffness. Bone (2014) 0.85
Effect of the cathepsin K inhibitor odanacatib administered once weekly on bone mineral density in Japanese patients with osteoporosis--a double-blind, randomized, dose-finding study. Osteoporos Int (2013) 0.85
An atraumatic femoral fracture in a patient with rheumatoid arthritis and osteoporosis treated with denosumab. Case Rep Rheumatol (2013) 0.85
Atypical femoral fracture following bisphosphonate treatment in a woman with osteogenesis imperfecta--a case report. Acta Orthop (2012) 0.84
Predictors of atypical femoral fractures during long term bisphosphonate therapy: a case series & review of literature. Indian J Med Res (2014) 0.84
Disparities in osteoporosis treatments. Osteoporos Int (2015) 0.84
Ulnar fractures with bisphosphonate therapy: a systematic review of published case reports. Osteoporos Int (2014) 0.83
Atypical femur fractures: a review of the evidence and its implication to clinical practice. Ther Adv Musculoskelet Dis (2011) 0.83
Pathogenesis, management and prevention of atypical femoral fractures. J Bone Metab (2015) 0.83
The fracture mechanics of human bone: influence of disease and treatment. Bonekey Rep (2015) 0.83
Long-term effects of bisphosphonate therapy: perforations, microcracks and mechanical properties. Sci Rep (2017) 0.82
Evaluation of fracture risk and potential drug holidays for postmenopausal women on long-term bisphosphonate therapy. Int J Womens Health (2014) 0.82
A case of an atypical femoral fracture associated with bacterial biofilm--pathogen or bystander? Osteoporos Int (2012) 0.82
Osteoporosis and treatments in Japan: management for preventing subsequent fractures. J Bone Miner Metab (2013) 0.82
Management of osteoporosis among the elderly with other chronic medical conditions. Drugs Aging (2012) 0.82
Role of zoledronic acid in the prevention and treatment of osteoporosis. Clin Interv Aging (2011) 0.82
Highly different risk estimates for atypical femoral fracture with use of bisphosphonates - debate must be allowed! Acta Orthop (2012) 0.82
Adherence to oral bisphosphonates and the risk of subtrochanteric and femoral shaft fractures among female medicare beneficiaries. Osteoporos Int (2014) 0.82
Atypical femur fractures in patients receiving bisphosphonate therapy: etiology and management. Eur J Orthop Surg Traumatol (2016) 0.81
Promotion of peri-implant bone healing by systemically administered parathyroid hormone (1-34) and zoledronic acid adsorbed onto the implant surface. Osteoporos Int (2013) 0.81
Stiffness and strength of bone in osteoporotic patients treated with varying durations of oral bisphosphonates. Osteoporos Int (2016) 0.81
Guidelines on the management and treatment of glucocorticoid-induced osteoporosis of the Japanese Society for Bone and Mineral Research: 2014 update. J Bone Miner Metab (2014) 0.81
Factors associated with atypical femoral fracture. Rheumatol Int (2015) 0.81
Evaluation of dental implants as a risk factor for the development of bisphosphonate-related osteonecrosis of the jaw in breast cancer patients. Odontology (2015) 0.81
Clinical experience with intravenous zoledronic acid in the treatment of male osteoporosis: evidence and opinions. Ther Adv Musculoskelet Dis (2013) 0.81
Dwarfism in mice lacking collagen-binding integrins α2β1 and α11β1 is caused by severely diminished IGF-1 levels. J Biol Chem (2011) 0.81
Long-term safety concerns of antiresorptive therapy. Rheum Dis Clin North Am (2011) 0.81
Bazedoxifene: the evolving role of third-generation selective estrogen-receptor modulators in the management of postmenopausal osteoporosis. Ther Adv Musculoskelet Dis (2012) 0.80
Runx1-mediated regulation of osteoclast differentiation and function. Mol Endocrinol (2014) 0.80
Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med (2007) 18.27
2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken) (2012) 12.07
One-year outcomes in survivors of the acute respiratory distress syndrome. N Engl J Med (2003) 11.77
A randomized trial of vertebroplasty for painful osteoporotic vertebral fractures. N Engl J Med (2009) 11.20
Functional disability 5 years after acute respiratory distress syndrome. N Engl J Med (2011) 9.96
American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum (2008) 9.94
Exemestane for breast-cancer prevention in postmenopausal women. N Engl J Med (2011) 8.19
The ventriloquist effect results from near-optimal bimodal integration. Curr Biol (2004) 7.89
Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res (2007) 6.76
The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med (2004) 6.55
Bisphosphonates and fractures of the subtrochanteric or diaphyseal femur. N Engl J Med (2010) 6.47
2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary. CMAJ (2010) 6.37
Recombinant human bone morphogenetic protein-2 for treatment of open tibial fractures: a prospective, controlled, randomized study of four hundred and fifty patients. J Bone Joint Surg Am (2002) 5.95
Matrix-embedded cells control osteoclast formation. Nat Med (2011) 5.77
Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res (2013) 5.76
Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial. Ann Intern Med (2006) 5.03
Atypical fractures of the femoral diaphysis in postmenopausal women taking alendronate. N Engl J Med (2008) 4.81
American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Care Res (Hoboken) (2010) 4.65
Fracture healing as a post-natal developmental process: molecular, spatial, and temporal aspects of its regulation. J Cell Biochem (2003) 4.34
The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT). J Bone Miner Res (2012) 4.15
Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT). Arthritis Rheum (2005) 4.12
Impact of androgen deprivation therapy on cardiovascular disease and diabetes. J Clin Oncol (2009) 4.07
A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis: the treatment of Early Aggressive Rheumatoid Arthritis Trial. Arthritis Rheum (2012) 4.01
When the world becomes 'too real': a Bayesian explanation of autistic perception. Trends Cogn Sci (2012) 3.89
Managing the care of patients receiving antiresorptive therapy for prevention and treatment of osteoporosis: executive summary of recommendations from the American Dental Association Council on Scientific Affairs. J Am Dent Assoc (2011) 3.76
Low-energy femoral shaft fractures associated with alendronate use. J Orthop Trauma (2008) 3.74
Initiation of tumor necrosis factor-α antagonists and the risk of hospitalization for infection in patients with autoimmune diseases. JAMA (2011) 3.58
Association of timing of surgery for hip fracture and patient outcomes. JAMA (2004) 3.51
The clinical importance of meniscal tears demonstrated by magnetic resonance imaging in osteoarthritis of the knee. J Bone Joint Surg Am (2003) 3.39
Teriparatide for acceleration of fracture repair in humans: a prospective, randomized, double-blind study of 102 postmenopausal women with distal radial fractures. J Bone Miner Res (2010) 3.33
Saccadic eye movements cause compression of time as well as space. Nat Neurosci (2005) 3.24
Vitamin D and health in adults in Australia and New Zealand: a position statement. Med J Aust (2012) 3.14
Interventions to improve osteoporosis treatment following hip fracture. A prospective, randomized trial. J Bone Joint Surg Am (2005) 3.12
Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs. Am J Med (2002) 3.10
First-line antiretroviral therapy with a protease inhibitor versus non-nucleoside reverse transcriptase inhibitor and switch at higher versus low viral load in HIV-infected children: an open-label, randomised phase 2/3 trial. Lancet Infect Dis (2011) 3.04
Bone grafts and bone graft substitutes in orthopaedic trauma surgery. A critical analysis. J Bone Joint Surg Am (2007) 3.04
Control of bone mass and remodeling by PTH receptor signaling in osteocytes. PLoS One (2008) 2.96
Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1). J Clin Endocrinol Metab (2012) 2.87
Incidence and demography of femur fractures with and without atypical features. J Bone Miner Res (2012) 2.85
Glucocorticoids act directly on osteoblasts and osteocytes to induce their apoptosis and reduce bone formation and strength. Endocrinology (2003) 2.84
The role of growth factors in the repair of bone. Biology and clinical applications. J Bone Joint Surg Am (2002) 2.82
From brittle to ductile fracture of bone. Nat Mater (2005) 2.76
Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus. J Bone Miner Res (2015) 2.74
Mortality associated with medical therapy versus elective colectomy in ulcerative colitis: a cohort study. Ann Intern Med (2014) 2.73
Skeletal involution by age-associated oxidative stress and its acceleration by loss of sex steroids. J Biol Chem (2007) 2.73
Musculoskeletal ultrasound in rheumatology: a radiologic perspective. Arthritis Rheum (2005) 2.71
Operative management of displaced femoral neck fractures in elderly patients. An international survey. J Bone Joint Surg Am (2005) 2.68
Activation of the hypoxia-inducible factor-1alpha pathway accelerates bone regeneration. Proc Natl Acad Sci U S A (2008) 2.65
Differential temporal expression of members of the transforming growth factor beta superfamily during murine fracture healing. J Bone Miner Res (2002) 2.62
The safety of infliximab, combined with background treatments, among patients with rheumatoid arthritis and various comorbidities: a large, randomized, placebo-controlled trial. Arthritis Rheum (2006) 2.54
The recent prevalence of osteoporosis and low bone mass in the United States based on bone mineral density at the femoral neck or lumbar spine. J Bone Miner Res (2014) 2.52
Association between vaccination for herpes zoster and risk of herpes zoster infection among older patients with selected immune-mediated diseases. JAMA (2012) 2.51
Daily and cyclic parathyroid hormone in women receiving alendronate. N Engl J Med (2005) 2.47
Rosiglitazone causes bone loss in mice by suppressing osteoblast differentiation and bone formation. Endocrinology (2004) 2.44
Proteasomal degradation of Runx2 shortens parathyroid hormone-induced anti-apoptotic signaling in osteoblasts. A putative explanation for why intermittent administration is needed for bone anabolism. J Biol Chem (2003) 2.44
Is high dose vitamin D harmful? Calcif Tissue Int (2012) 2.43
Joint injury, repair, and remodeling: roles in post-traumatic osteoarthritis. Clin Orthop Relat Res (2004) 2.43
Sexual differentiation, pregnancy, calorie restriction, and aging affect the adipocyte-specific secretory protein adiponectin. Diabetes (2003) 2.40
Tumour necrosis factor antagonist use and associated risk reduction of cardiovascular events among patients with rheumatoid arthritis. Ann Rheum Dis (2010) 2.39
Vitamin D and musculoskeletal health, cardiovascular disease, autoimmunity and cancer: Recommendations for clinical practice. Autoimmun Rev (2010) 2.38
Recombinant human parathyroid hormone (1-34) [teriparatide] improves both cortical and cancellous bone structure. J Bone Miner Res (2003) 2.38
Microarchitectural deterioration of cortical and trabecular bone: differing effects of denosumab and alendronate. J Bone Miner Res (2010) 2.37
Efficacy of autologous platelet-rich plasma use for orthopaedic indications: a meta-analysis. J Bone Joint Surg Am (2012) 2.31
Osteocyte apoptosis is induced by weightlessness in mice and precedes osteoclast recruitment and bone loss. J Bone Miner Res (2006) 2.31
Hypoparathyroidism in the adult: epidemiology, diagnosis, pathophysiology, target-organ involvement, treatment, and challenges for future research. J Bone Miner Res (2011) 2.30
Toward excellence in testosterone testing: a consensus statement. J Clin Endocrinol Metab (2010) 2.28
The biology of fracture healing. Injury (2011) 2.26
Administrative codes combined with medical records based criteria accurately identified bacterial infections among rheumatoid arthritis patients. J Clin Epidemiol (2008) 2.25
Quality of life in MAP.3 (Mammary Prevention 3): a randomized, placebo-controlled trial evaluating exemestane for prevention of breast cancer. J Clin Oncol (2014) 2.25
Differential inhibition of fracture healing by non-selective and cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs. J Orthop Res (2003) 2.24
A 52-kb deletion in the SOST-MEOX1 intergenic region on 17q12-q21 is associated with van Buchem disease in the Dutch population. Am J Med Genet (2002) 2.21
Longitudinal evolution of bone mineral density and bone markers in human immunodeficiency virus-infected individuals. Clin Infect Dis (2003) 2.20
Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: thirty-six-month results of a randomized, double-blind, controlled trial. Arthritis Rheum (2009) 2.16
Excess mortality in men compared with women following a hip fracture. National analysis of comedications, comorbidity and survival. Age Ageing (2010) 2.15
Rates of malignancy associated with juvenile idiopathic arthritis and its treatment. Arthritis Rheum (2012) 2.15